COLL Gains on ADHD Portfolio
Collegium Pharmaceutical's attention deficit hyperactivity disorder portfolio is gaining attention, driving the stock higher. The company's focus on ADHD treatments is a key factor in its growth.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.